Epimune’s goal is to revolutionize diagnosis and monitoring of patients with disorders of the immune system
Using epigenetics, Epimune develops & commercializes molecular diagnostic tests for immune cell quantification from a drop of blood
09 Aug 2021
New Article on using Epimune's epigenetic immune cell quantification as a second-tier test to reduce non-actionable secondary findings and false positive referrals in newborn screening for severe combined immunodeficiency published in Journal of Clinical Immunology
For a Spanish version of this video please click here!